About
A Chinese peptide manufacturer global buyers can audit.
Headquartered in Shanghai, China, Lyochem manufactures, documents, and ships research and cosmetic peptides under one quality system. Our buyers include compounding pharmacies, med-aesthetic brands, research labs, biotech / pharma R&D groups, and distributors operating across multiple regions.
How we're organized
Four functions, one quality system.
Lyochem is structured so every buyer-facing decision, pricing, lead time, COA, regulatory review, passes through people who own the relevant function. Inquiries land with sales, but quality and regulatory review every quote before it goes out.
Function
Manufacturing
Oversees synthesis, purification, lyophilization, vial filling, and packaging across all production lines. Final sign-off on production schedules and shop-floor changes.
Tenure
10–15 years in synthetic peptide manufacturing
Background
Solid-phase peptide synthesis at a major Chinese CDMO; pharma-API process development for both research-grade and pharmacy-grade material.
Function
Quality Assurance
Owns analytical methods, stability program, batch release, and COA approval workflow. No batch ships without QA sign-off on the analytical packet.
Tenure
8–12 years in pharmaceutical QA
Background
GMP-aligned analytical method development (HPLC, mass spec, Karl Fischer, LAL endotoxin); USP/EP/CP pharmacopeia compliance.
Function
R&D · Custom Synthesis
Sequence design, non-standard modifications (PEG conjugation, lipidation, copper coordination, D-amino-acid incorporation, intramolecular disulfide bridging), pilot-scale process development.
Tenure
12+ years in synthetic peptide R&D
Background
Doctoral-level training in peptide chemistry; prior experience with custom-sequence synthesis for both research and clinical-development programs.
Function
Global Sales & Regulatory
Direct contact for buyers worldwide. Reviews each inquiry for regulatory fit in the destination market before pricing, written advisory on FDA 503A/503B, EMA, MENA / APAC / LATAM frameworks.
Tenure
8–10 years in pharma B2B sales + regulatory
Background
Cross-border peptide-active commercial relationships; regulatory tracking across major markets including FDA PCAC briefings, EMA scientific advice, and national medicines agency import frameworks.
Individual leader identities are disclosed under NDA at the commercial-relationship stage rather than on the public site. Avatars above are monogram-style identifiers, not photographs, they represent the function, not a specific person.
How we work
Operating since 2013 · 13+ years in peptide manufacturing.
Lyochem started in 2013 as a peptide synthesis operation supplying research-grade material to academic labs and CROs, and grew into an end-to-end peptide manufacturer in China, covering synthesis, chromatography purification, lyophilization, vial filling, and packaging under a single quality system.
Today, the same facility produces material for compounding pharmacies, cosmetic and med-aesthetic OEM clients, biotech R&D groups working on custom sequences, and a distributor network across multiple regions.
Our positioning is deliberately not the cheapest in the market. We invest in documentation (batch-specific COA, HPLC + Mass Spec, sequence verification, stability studies) and in regulatory awareness, every quote is reviewed for fit with the destination market's rules before pricing.
We are actively tracking the FDA Pharmacy Compounding Advisory Committee review of seven peptides expected in July 2026 (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) and have already aligned our documentation depth with the standards the 503A bulks list will demand.
Request a data packet.
First reply under 12 hours from a synthesis chemist or analytical contact — not a templated auto-response. Lot-specific HPLC chromatogram, ESI-MS identity, MS/MS sequence (on request), KF water, and stability data returned with the quote.